1. Home
  2. TBPH vs CHW Comparison

TBPH vs CHW Comparison

Compare TBPH & CHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • CHW
  • Stock Information
  • Founded
  • TBPH 2013
  • CHW 2007
  • Country
  • TBPH United States
  • CHW United States
  • Employees
  • TBPH N/A
  • CHW N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • CHW Investment Managers
  • Sector
  • TBPH Health Care
  • CHW Finance
  • Exchange
  • TBPH Nasdaq
  • CHW Nasdaq
  • Market Cap
  • TBPH 452.3M
  • CHW 439.4M
  • IPO Year
  • TBPH N/A
  • CHW N/A
  • Fundamental
  • Price
  • TBPH $9.32
  • CHW $6.97
  • Analyst Decision
  • TBPH Buy
  • CHW
  • Analyst Count
  • TBPH 4
  • CHW 0
  • Target Price
  • TBPH $13.75
  • CHW N/A
  • AVG Volume (30 Days)
  • TBPH 202.5K
  • CHW 195.2K
  • Earning Date
  • TBPH 02-26-2025
  • CHW 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • CHW 9.27%
  • EPS Growth
  • TBPH N/A
  • CHW N/A
  • EPS
  • TBPH N/A
  • CHW N/A
  • Revenue
  • TBPH $63,192,000.00
  • CHW N/A
  • Revenue This Year
  • TBPH $11.41
  • CHW N/A
  • Revenue Next Year
  • TBPH $37.36
  • CHW N/A
  • P/E Ratio
  • TBPH N/A
  • CHW N/A
  • Revenue Growth
  • TBPH 15.93
  • CHW N/A
  • 52 Week Low
  • TBPH $7.44
  • CHW $5.07
  • 52 Week High
  • TBPH $10.90
  • CHW $6.54
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 47.75
  • CHW 52.05
  • Support Level
  • TBPH $8.85
  • CHW $6.92
  • Resistance Level
  • TBPH $10.05
  • CHW $7.03
  • Average True Range (ATR)
  • TBPH 0.38
  • CHW 0.07
  • MACD
  • TBPH 0.01
  • CHW 0.01
  • Stochastic Oscillator
  • TBPH 38.75
  • CHW 66.73

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CHW Calamos Global Dynamic Income Fund

Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.

Share on Social Networks: